Post by
francoisl13 on Jul 20, 2023 10:16am
Coactiv+ - no news, no sales update, total radio silence....
It is amazing to see that KNE did not announce it's first sale of Coactiv+ in the USA (through Progenacare) yet. The deal with Progenacare was made prior to the FDA approval so, one would imagine that Progenacare customers were told in advance that the product was coming and still no news. KNE did not even bother to do a press release to confirm the receipt of the 500K upfront payment from Progenacare. I understand that the KNE team is rather small but investors communication is critical for a biotech of that size in order to keep the investment community interest and we fail big time on that front.
The above being said, it looks like we are on the right path in regards to products development, approval, trials, etc.... but need more to get the investment community interest.
GLTA
Comment by
RoyMax123 on Jul 20, 2023 10:36am
They already said in their last conf call that they need to ramp up the production before they start selling, so they hope to have revenue in Q4. And since there's always some delays it probably mean Q1 next year at best.
Comment by
francoisl13 on Jul 20, 2023 10:48am
Yup, I've listened to the conf. call but, the comment made is linked to production and product shipment. It doesn't prevent them to announce that they got orders for the product in order to keep the market aware about the product traction in the US market. It would also help raise the awareness and keep the interest from the investment community. Only my two cents...:)